Adding Zilovertamab Vedotin to Standard Care Shows Strong ORR for DLBCL
Zilovertamab vedotin plus R-GemOx elicits responses in patients with relapsed or refractory diffuse large B-cell lymphoma.
Related Articles
BCG Shortage Warrants Treatment Shifts, New Treatment Strategies in Bladder Cancer
Bogdana Schmidt, MD, MPH, details the role of BCG in bladder cancer and navigating BCG shortages across the board during Bladder Cancer Awareness Month.
OVATION-3 Trial of IMNN-001 Seeks to Confirm Feasibility of Targeting IL-12 to Boost Immune Responses in Ovarian Cancer
Premal Thaker, MD, MS, discusses prior data supporting the ongoing investigation of IMNN-001 plus perioperative chemotherapy in ovarian cancer.
Updated STARGLO Data Show Maintained OS Benefit With Glofitamab Plus Chemo in R/R DLBCL
Two-year follow-up data continued to show an overall survival benefit with glofitamab plus chemotherapy in relapsed/refractory DLBCL.
China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL
Tafasitamab plus lenalidomide has received NMPA approval for patients with relapsed/refractory DLBCL who are ineligible for ASCT.
FDA’s ODAC Votes Against Risk/Benefit Profile of UGN-102 in Recurrent, Low-Grade, Intermediate-Risk NMIBC
The FDA’s ODAC voted against the risk/benefit profile of UGN-102 for recurrent, low-grade, intermediate-risk non–muscle-invasive bladder cancer.
Inavolisib Plus Palbociclib and Fulvestrant Improves OS in PIK3CA-Mutant, HR+/HER2– Breast Cancer
Inavolisib plus palbociclib and fulvestrant improved OS in PIK3CA-mutant, HR-positive, HER2-negative, endocrine-resistant advanced breast cancer.
Navigating CML Treatment: A Patient-Centered Approach
Jorge Cortes, MD, and Stephen A. Strickland Jr, MD, MSCI,discuss how in the management of chronic myeloid leukemia (CML), clinicians must carefully monitor early treatment…
Emerging Treatment Approaches for HR+/HER2– Early-Stage Breast Cancer
Panelists discuss how emerging treatment strategies, including the use of CDK4/6 inhibitors and personalized risk stratification, are transforming the management of high-risk HR+/HER2– early-stage breast…
T-DXd Plus Pertuzumab Could Disrupt First-Line SOC in HER2+ Metastatic Breast Cancer
Tess O’Meara, MD, discusses the implications of data from the DESTINY-Breast09 trial of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.
COMRADE Trial: Olaparib Plus Radium-223 Improves rPFS Survival in CRPC
In an interview, Rana McKay, MD, discusses findings from the COMRADE trial evaluating olaparib plus radium-223 in prostate cancer presented at the 2025 ASCO Annual…
